Anti-ADC Antibody Antibody (Cantuzumab)

Cantuzumab is a monoclonal antibody designed to target and bind to specific antigens on the surface of cancer cells. It belongs to a class of therapeutics called antibody-drug conjugates (ADCs), which combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. Cantuzumab specifically targets the CanAg antigen, which is often overexpressed in certain types of cancer, such as colorectal cancer, pancreatic cancer, and certain types of lung cancer. By binding to this antigen, Cantuzumab can deliver its cytotoxic payload directly to cancer cells, thereby minimizing damage to healthy cells and increasing the effectiveness of treatment.